TOP BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES SECRETS

The current work examined the potential of using ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in equally p53 wild-variety (WT) breast tumor cells As well as in cells missing useful p53 possibly by itself or in combination with tamoxifen, whilst the effectiveness of ABBV-744 wa